Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Found vs Sesame Care

Two GLP-1 desks, one scoreboard. We put Found and Sesame Care head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.

Higher Brief ScoreNo. 5 · Grade B+

Found

Visit Found Full brief →
vs
No. 6 · Grade B+

Sesame Care

Visit Sesame Care Full brief →

The verdict

Found takes this head-to-head.

Found scores 88 to 87 on our six-factor Brief Score — A coaching-first program with the lowest identical price on both molecules — if you want the coaching lock-in that comes with it.

That doesn't make Sesame Care a bad call — it's best for shoppers who want genuine fda-approved brand-name glp-1s and the ability to pick their own provider and see the price up front, rather than one fixed compounded program. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
88
84
Supply Reliability
88
92
Transparency
88
94
Access Breadth
88
84
Clinical Oversight
90
80
Track Record
86
92
FoundBrief Score 88 · 87Sesame Care

Price, coverage & the tracker

FoundSesame Care
Brief Score88/100 (B+)87/100 (B+)
Semaglutide$129/moFrom $149/mo (brand Wegovy pill)
Tirzepatide$129/moBrand Zepbound (price varies)
CoverageAll 50 statesNationwide marketplace
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
On the trackerStableprice stableStableprice stable

Found: Lowest identical-price line on the board — but bundled into a coaching subscription.

Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.